{"schema_version":"secwatch.filing_event.v1","accession":"0001386570-26-000042","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2026-08-04T20:03:29+00:00","discovered_at":"2026-08-04T20:05:02.728163+00:00","generated_at":"2026-08-04T20:05:32.770505+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Niagen Bioscience Q2 net sales $29.8M, net income $1.0M; launches pharmaceutical program targeting rare diseases","bullets":["Net sales $29.8M ($24.2M Tru Niagen); gross margin 64.8%; net income $1.0M ($0.01 EPS); adjusted EBITDA $3.0M.","Launched Niagen Plus telehealth platform with at-home injection kit; received LegitScript certification for advertising.","Introduced NB4168 for rare genetic diseases targeting Ataxia-Telangiectasia; received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations.","Appointed Abhijit Kale as Senior Director of Global External Research to lead pharmaceutical program.","2026 outlook: e-commerce growth 10-15% YoY; ingredient business expected lower; expects increased operating expenses."],"urls":{"canonical":"https://secwatch.observer/filing/0001386570-26-000042","json":"https://secwatch.observer/filing/0001386570-26-000042.json","markdown":"https://secwatch.observer/filing/0001386570-26-000042.md","text":"https://secwatch.observer/filing/0001386570-26-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000138657026000042/0001386570-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000138657026000042/cdxc-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:05:32.770505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}